» Articles » PMID: 19424621

Significance of DNA Methyltransferase-1 and Histone Deacetylase-1 in Pancreatic Cancer

Overview
Journal Oncol Rep
Specialty Oncology
Date 2009 May 9
PMID 19424621
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Epigenetic modifications play an important role during carcinogenesis. The main goal of this study was to examine expression levels of two critical enzymes, DNA methyltransferase-1 (DNMT1) and histone deacetylase-1 (HDAC1), by immunohistochemistry (IHC) in human pancreatic cancer and precancerous lesions: 20 foci containing normal ductal epithelial cells without an inflammatory back-ground (DE), 30 containing ductal epithelial cells with an inflammatory background (DEI), 48 of pancreatic intraepithelial neoplasia-1A (PanIN-1A), 103 of PanIN-1B, 99 of PanIN-2, 30 of PanIN-3, 18 of intraductal papillary mucinous neoplasm A (IPMA), 10 of IPMB, 20 of IPMC, and 54 of pancreatic ductal adenocarcinoma (PDAC). The expression levels of both DNMT1 and HDAC1 increased from normal to precancerous lesions to pancreatic cancer, in a malignancy-dependent manner. Correlations between expression levels and clinicopathological features of the 54 PDAC patients were also analyzed. The expression of DNMT1 significantly correlated with nerve infiltration, degree of tumor differentiation and TNM staging (p<0.05), while that of HDAC1 correlated with proliferative activity, degree of tumor differentiation and TNM staging (p<0.05). Patients with higher expression of DNMT1 and/or HDAC1 had an overall lower survival than those with lower expression (p<0.05). Higher expression of DNMT1 and HDAC1 correlated with advanced stages of the disease and reflect the malignancy of pancreatic carcinoma. They may become new prognostic markers and potential therapeutic targets for pancreatic cancer.

Citing Articles

Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma.

Oyon D, Lopez-Pascual A, Castello-Uribe B, Uriarte I, Orsi G, Llorente S J Exp Clin Cancer Res. 2025; 44(1):13.

PMID: 39810240 PMC: 11734372. DOI: 10.1186/s13046-024-03268-5.


Inhibiting stromal Class I HDACs curbs pancreatic cancer progression.

Liang G, Oh T, Hah N, Tiriac H, Shi Y, Truitt M Nat Commun. 2023; 14(1):7791.

PMID: 38057326 PMC: 10700526. DOI: 10.1038/s41467-023-42178-6.


The Association Between Serum Riboflavin and Flavin Mononucleotide With Pancreatic Cancer: Findings From a Prospective Cohort Study.

Paragomi P, Wang R, Huang J, Midttun O, Ulvik A, Ueland P Pancreas. 2023; 52(2):e127-e134.

PMID: 37523604 PMC: 10399971. DOI: 10.1097/MPA.0000000000002220.


Epigenetic reprogramming in pancreatic premalignancy and clinical implications.

Zhang W, Jiang T, Xie K Front Oncol. 2023; 13:1024151.

PMID: 36874143 PMC: 9978013. DOI: 10.3389/fonc.2023.1024151.


Epigenetic Regulations of Perineural Invasion in Head and Neck Squamous Cell Carcinoma.

Hurnik P, Chyra Z, Sevcikova T, Stembirek J, Smesny Trtkova K, Gaykalova D Front Genet. 2022; 13:848557.

PMID: 35571032 PMC: 9091179. DOI: 10.3389/fgene.2022.848557.